Development of Cancer Immunoprevention in a High-Risk Population of Canadian Inuits: Characterization of Frame-Shift Neoantigen Expression in Homozygous Individuals and Carriers of PMS2 Mutations

加拿大因纽特人高危人群癌症免疫预防的发展：纯合个体和 PMS2 突变携带者移码新抗原表达的特征

• 批准号: 10725425
• 负责人: LEONARD FREEDMAN
• 金额: $ 2.47万
• 依托单位: LEIDOS BIOMEDICAL RESEARCH, INC.
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-08-31 至 2022-08-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10725425
• 关键词: Blood; Cancer Prevention Trial; DNA; Development; Family member; Frameshift Mutation; Hereditary Nonpolyposis Colorectal Neoplasms; Immunoprevention; Individual; Inuits; Malignant Neoplasms; Mucous Membrane; Mutation; PMS2 gene; Preventive; RNA; Reagent; Recurrence; Sampling; Syndrome; Testing; Tumor Tissue; Vaccines; base; cancer prevention; cohort; high risk; high risk population; mouse model; neoantigen vaccine; neoantigens; next generation sequencing; tumor; vaccine strategy

Project hypothesizes that the recurrent frame-shift mutations observed in Lynch Syndrome will also occur in CMMRD Syndrome and that the neoantigen vaccine strategy and reagents will be directly relevant to cancer prevention in CMMRD Syndrome.

项目假设Lynch综合征中观察到的复发性移框突变也会发生在CMMRD综合征中，新抗原疫苗策略和试剂将与CMMRD综合征的癌症预防直接相关。